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Abstract
Background and Objectives—Chronic kidney disease is a persistent chronic health condition 
commonly seen in pediatric nephrology programs. Our study aims to evaluate the sensitivity of the 
Patient Reported Outcomes Measurement Information System (PROMIS) pediatric instrument to 
indicators of disease severity and activity in pediatric chronic kidney disease.
Methods—This cross sectional study included 233 children 8–17 years old with chronic kidney 
disease from 16 participating institutions in North America. Disease activity indicators, including 
hospitalization in the previous 6 months, edema, and number of medications consumed daily, as 
well as disease severity indicators of kidney function and coexisting medical conditions were 
captured. PROMIS domains, including depression, anxiety, social-peer relationships, pain 
interference, fatigue, mobility, and upper extremity function, were administered via web-based 
questionnaires. Absolute effect sizes (AES) were generated to demonstrate the impact of disease 
on domain scores. Four children were excluded because of missing GFR estimations.
Results—221 of the 229 children included in the final analysis completed the entire PROMIS 
questionnaire. Unadjusted PROMIS domains were responsive to chronic kidney disease activity 
indicators and number of coexisting conditions. PROMIS domain scores were worse in the 
presence of recent hospitalizations (depression AES 0.33, anxiety AES 0.42, pain interference 
AES 0.46, fatigue AES 0.50, mobility AES 0.49), edema (depression AES 0.50, anxiety AES 
0.60, pain interference AES 0.77, mobility AES 0.54) and coexisting medical conditions (social 
peer-relationships AES 0.66, fatigue AES 0.83, mobility AES 0.60, upper extremity function AES 
0.48).
Conclusions—The PROMIS pediatric domains of depression, anxiety, social-peer relationships, 
pain interference, and mobility were sensitive to the clinical status of children with chronic kidney 
disease in this multi-center cross sectional study. We demonstrated that a number of important 
clinical characteristics including recent history of hospitalization and edema affected patient 
perceptions of depression, anxiety, pain interference, fatigue and mobility. The PROMIS 
instruments provide a potentially valuable tool to study the impact of chronic kidney disease. 
Additional studies will be required to assess responsiveness in PROMIS score with changes in 
disease status over time.
Keywords
Patient reported outcomes; quality of life; transplant; end stage kidney disease; chronic kidney 
disease; pediatrics; children
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Individuals with chronic kidney disease represent a growing population in adult and 
pediatric practices. This has resulted in a drive to optimize patient care and outcomes [1]. 
Chronic kidney disease in children encompasses a broad range of etiologies including 
congenital anomalies of the kidney and urinary tract, cystic kidney diseases and 
glomerulopathies. In addition to the clinical measures of kidney function, assessment of 
health-related quality of life through patient reported outcomes can elucidate and quantify 
the patient perspective on health and disease.
The impact of chronic kidney disease on the health-related quality of life of pediatric 
patients has been increasingly studied over the past several years. Patients with end stage 
kidney disease receiving dialysis have been shown to have significantly lower health-related 
quality of life in all domains measured on the generic Pediatric Inventory of Quality of Life 
Scales (Peds QL 4.0™) and the end stage kidney disease specific PedsQL 3.0™ [2–4]. 
Studies examining the impact of renal transplant on the health-related quality of life of 
patients have yielded divergent results [2, 5, 6]. Gerson et al recently demonstrated through 
the use of the PedsQL 4.0™ that children with mild to moderate chronic kidney disease had 
significantly lower physical, emotional, school, and social domain scores [7]. Each of these 
studies has confirmed the negative impact of chronic kidney disease on health-related 
quality of life in children.
The Patient Reported Outcomes Measurement Information System (PROMIS) project was 
established as part of the National Institutes of Health Roadmap Initiative to create item 
banks for both adults and children, which are publically available, efficient, precise, and 
valid across a variety of diseases to assess patient reported outcomes (www.nihpromis.org). 
In the initial phase of PROMIS, 9 item banks specific to selected symptoms and quality of 
life were developed using qualitative and quantitative methods to measure child self-
reported outcomes: depression, anxiety, social-peer relationships, pain interference, fatigue, 
mobility, upper extremity function, anger, and asthma impact in children 8–17 years old [8–
12]. Previously most health-related quality of life research instruments utilized classical test 
theory in their development [13], but the PROMIS instrument was developed using newer 
psychometric techniques also referred to as item response theory [14]. Item response theory 
has allowed PROMIS to create banks of items that measure an underlying trait (e.g., 
Fatigue) and gives the user (researcher, clinician) the option to use any subset of the items in 
the bank to measure the trait. Any subset of the items can be combined to generate a score 
(PROMIS score) that is comparable with other studies using items from the bank. PROMIS 
also developed item banks that do not require attribution of a symptom to a disease. This 
allows comparison of scores across diseases or for patients with multiple chronic diseases. 
Currently, the PROMIS item banks are undergoing validity studies in a variety of 
populations including children with asthma, sickle cell disease, cancer, nephrotic syndrome, 
inflammatory bowel disease, and obesity [15–17]. The validation of the PROMIS instrument 
becomes particularly important in pediatric clinical research and pediatric therapeutics as 
patient reported outcomes are becoming standard clinical trial endpoints and their use is 
encouraged by the Food and Drug Administration [18].
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This study aims to evaluate the sensitivity of the PROMIS instruments to pediatric chronic 
kidney disease severity (Stage I–III, Stage IV–V, and Renal Transplant), and activity 
indicators, such as edema and recent hospitalizations. We hypothesized that the PROMIS 
instruments would demonstrate worse patient reported outcomes in children with a greater 
degree of chronic kidney disease severity and activity.
METHODS
This cross sectional study was conducted by the Midwest Pediatric Nephrology Consortium 
(MWPNC) and included 233 pediatric patients from 16 participating member institutions. 
Each site obtained individual institutional IRB approval. Parents and children gave informed 
consent and assent respectively, prior to performing the study.
Training study team members
Research personnel at each site received web-based training in study procedures; the study 
operations manual was a reference tool for study conduct, quality control, and recruitment. 
Ongoing education of site personnel occurred during investigator and coordinator 
conference calls.
Eligibility
The PROMIS kidney cohort study included children 8–17 years old with chronic kidney 
disease defined as having end stage kidney disease requiring dialysis, a kidney transplant, or 
estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2 [19]. Eligibility criteria 
included the ability to speak and read English. Exclusion criteria included co-existing 
medical, psychiatric, or cognitive impairments that would prevent the patient from 
answering the computerized questionnaire. Children with nephrotic syndrome were not 
included in this analysis as this population has been previously reported [16].
Study Procedures
The parent completed the Family and Medical Information form, which included 
relationship to child, guardian education level, socioeconomic, and disease specific 
questions. Child characteristics included: gender, age, race, ethnicity, disease etiology, 
dialysis, transplant, co-existing conditions, hospitalizations in the previous 6 months, 
surgery in the previous 12 months, number of medications, corticosteroid therapy, self-rated 
edema status, and the guardian’s perception of the child’s weight status (underweight, 
healthy weight or overweight). Clinical data such as diagnosis and eGFR were obtained 
from the patient medical record by the local investigators. Chronic kidney disease stage was 
assigned based on eGFR as defined by the Kidney Disease Outcomes Quality Initiative [20].
The children completed the domains related to depression, anxiety, social-peer relationships, 
pain interference, fatigue, mobility, and upper extremity function. The definitions of the 
domains are located at http://www.nihpromis.org/measures/domainframework2. All of the 
PROMIS items use the context statement “In the past 7 days.” Responses include five 
options ranging from “never” to “almost always” in the majority of domains and from “with 
no trouble” to “not able to do” for the physical functioning measures. Each pediatric 
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PROMIS domain generates a T-score where 50 is the mean and 10 the standard deviation in 
the initial PROMIS calibration population. Higher scores indicate more of the measured 
symptom, thus signifying worse symptoms of depression, anxiety, fatigue, and pain 
interference and better functioning for mobility, upper extremity function, and peer 
relationships. These measures have been previously tested in a large group of children and 
adolescents, confirming their unidimensionality and the extent to which each item was 
associated with the measured variable (www.assessmentcenter.net) [8, 10–12, 14]. The trait-
level-specific reliabilities of scores on the pediatric PROMIS measures have been ≥ 0.85 in a 
2 to 4 standard deviation score range of the domains being measured [10–12, 14].
In order to decrease the response burden, a sampling plan was devised and is summarized in 
Table 1. Briefly, participants were randomly assigned to one of two study arms by the 
Assessment Center after they were registered to take the survey, which included the 
assignment of the long form for either the pain interference or fatigue domain and the short 
or long form version of all the other domains. Using this strategy, children completed 70 to 
90 questions over 30 to 40 minutes.
Statistical analysis
Frequencies and percentages were calculated for demographic and clinical characteristics. 
Means and standard deviations were calculated for eGFR scores and number of medications. 
For the purpose of domain analysis, chronic kidney disease was divided in stage I–III, stage 
IV–V, and renal transplant. Mean scores as well as standard deviations were calculated for 
each of the 7 domains by long and short-form. To assess the association of long versus 
short-form scores, Pearson’s correlations were calculated where applicable. The long and 
short form domain scores for all domains were very highly correlated with Pearson’s r 
ranging 0.95–1.0. Consequently, short-form mean scores are presented in this manuscript 
and compared across the study sample by chronic kidney disease stage with greater stage 
showing an increase in disease severity, indicating poorer kidney function and transplant 
status. Mean scores were also compared across the disease activity indicators of recent 
hospitalization, recent surgery, edema status and number of coexisting medical conditions. 
Because the domain variables were not normally distributed, comparisons were also 
performed using non-parametric Wilcoxon test for two-sample comparison and Kruskal-
Wallis test for multiple-sample comparison. Published guidelines were used to define the 
magnitude of absolute effect sizes (AES) based on the ranges of Cohen’s d values: 
“small”=0.0–0.4, “medium” =0.5–0.7 and “large” ≥0.8 [21]. For variables with more than 
one category, Cohen’s d was calculated using the categories with the highest and lowest 
means. Simultaneous regression analyses were conducted to assess and interpret the 
association of child characteristics with each of the 5 domains with complete scores. All 
statistical analyses were conducted using SAS v9.2.
Results
Child demographic and disease characteristics and guardian demographic are presented in 
Table 2. Four children were excluded because of missing GFR estimations. There were 229 
children in the final analysis including those with chronic kidney disease stage I–III (N=106, 
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46%), stage IV–V (N=38, 17%), and renal transplant (N=85, 37%). Underlying chronic 
kidney disease etiology included congenital urologic abnormalities (N=114, 50%), 
glomerular disease (N=68, 30%), and other (N=47, 21%). About one-third of the children 
reported recent hospitalizations (N=75, 33%). Twelve percent (N=27) reported presence of 
edema, 11 had glomerular disease and 16 had non-glomerular disease. Fifty (22%) children 
reported 2 or more co-existing medical conditions. A total of 8 children were missing one or 
more of the PROMIS domain scores. Four children had missing scores for one of the 
PROMIS domains and four children ended the survey early. Missing data, from either 
incomplete assessments or missing a single domain, was not associated with any of the 
following explanatory variables of interest: CKD stage, transplant, hospitalizations, surgery, 
edema, number of medications, and coexisting medical conditions, or by patient age. Tables 
3 and 4 show the actual number of children that completed each domain.
Analysis of Disease Characteristics and PROMIS domains
Table 3 shows domain scores for depression, anxiety, and social-peer relationships. Markers 
of disease activity including recent hospitalizations and edema predicted worse scores. 
Patients who experienced recent hospitalizations had worse depression and anxiety scores 
(AES 0.33 and 0.42, respectively). The presence of edema was also associated with more 
difficulties with depression and anxiety (AES 0.50 and 0.60, respectively). Co-existing 
conditions were also associated with worse social-peer relationship scores (AES 0.66).
Table 4 includes domain scores for pain interference, fatigue, mobility and upper extremity 
function separately. Chronic kidney disease severity was associated with worse mobility 
(AES 0.41) scores. Markers of disease activity including recent hospitalizations and edema 
predicted worse domain scores. Recent hospitalization was associated with worse scores 
pain interference (AES 0.46), fatigue (AES 0.50), and mobility (AES 0.49). The presence of 
edema was associated with significantly worse scores in pain interference (AES 0.77), 
mobility (AES 0.54) and was borderline with fatigue (AES 0.63, p=0.05). The number of 
coexisting medical conditions was associated with worse fatigue (AES 0.83), mobility (AES 
0.60) and upper extremity function (AES 0.48).
Children with glomerular disease were analyzed separately as a sensitivity analysis (data not 
shown). The domain scores did not differ significantly between children with glomerular 
diseases and the remainder of the study population with the exception of upper extremity 
function where children with glomerular disease had significantly better function (p<0.05).
Figure 1 shows a comparison between the children with chronic kidney disease reported in 
this manuscript and those with nephrotic syndrome previously reported [16]. The domain 
scores did not differ significantly between children with chronic kidney disease and children 
with nephrotic syndrome except in upper extremity functioning where children with 
nephrotic syndrome had significantly better function (p<0.05).
Multivariate Results
Multivariate results are reported in Table 5. Overall, the PROMIS instruments were 
sensitive to markers of chronic kidney disease activity including recent hospitalization and 
edema. Children with hospitalization in the past 6 months had a 4-point worse score for 
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depression and a 5-point worse score for anxiety (p<0.05, Table 5). Children with edema on 
average had a 6-point worse score for depression, 6-point worse score for anxiety, and 4-
point worse score for mobility (p<0.05, Table 5). Co-existing medial conditions also 
predicted worse PROMIS scores. Those with two or more co-existing medical conditions 
had on average a 4-point worse score in depression, 5-point worse score in anxiety, 8-point 
worse score in social-peer relationships, 4-point worse score in mobility, and 3-point worse 
score in upper extremity function (p<0.05).
DISCUSSION
As children with chronic kidney disease survive into adulthood, the impact of chronic illness 
on their health-related quality of life has been increasingly recognized and studied, yet not 
routinely addressed in clinical practice. We present a multi-center study evaluating the 
PROMIS instrument as a measure of patient reported outcomes in children with chronic 
kidney disease. We demonstrate that the PROMIS instrument distinguishes between children 
with chronic kidney disease with and without markers of disease activity. We also report a 
novel finding demonstrating the importance of co-existing medical conditions on the patient 
reported outcomes of patients with chronic kidney disease. The PROMIS instruments are 
potentially valuable tools for researchers who seek to study the impact of chronic kidney 
disease on children.
Recent studies have indicated that children with chronic kidney disease or nephrotic 
syndrome are vulnerable to health-related quality of life challenges involving impact on 
physical, school, emotional, and social functioning [7, 16, 22]. In children who are initiating 
dialysis, psychological problems have been identified and often persist into adulthood [23, 
24]. However there are limited studies offering insight into the characteristics of the disease 
experience that may impact health-related quality of life. Our group has recently reported on 
the importance of edema in children with nephrotic syndrome and its impact on patient 
reported outcomes as a measure of health-related quality of life [16]. Previous studies in 
children with chronic kidney disease that investigated these issues have focused on long-
term factors associated with chronic kidney disease such as short stature and anemia [25, 
26], but have not investigated distinct near and long-term factors influencing patient 
reported outcomes. In this study, we show that the PROMIS instrument identified specific 
near and long-term factors affecting patient reported outcomes including hospitalization in 
the past 6 months, current edema status, and co-existing conditions.
The need for hospitalization often represents a worsening of clinical status, but also 
represents a significant upheaval in a child’s life with separation from their normal routine 
and interaction with friends, family, and school. Our study demonstrated that children with 
chronic kidney disease who have been hospitalized in the past 6 months had significantly 
worse scores for depression, anxiety, pain, fatigue, and mobility. Furthermore, in 
multivariate analysis, the need for hospitalization remained predictive of worse depression 
and anxiety in children with chronic kidney disease. These results are consistent with 
previous reports showing that children with chronic kidney disease had significant 
psychosocial burdens [7, 22, 27, 28].
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Edema represents one of the most visibly evident symptoms of chronic kidney disease. The 
impact of edema on patients includes physical appearance, mobility challenges, and pain. 
Our team recently reported worse health-related quality of life in children with nephrotic 
syndrome with edema in the domains of anxiety, pain interference, fatigue, and mobility 
[16]. PROMIS scores demonstrated similar findings in children with chronic kidney disease 
showing that the presence of edema was associated with worse depression, anxiety, pain, 
fatigue, and mobility. It is understandable that children would have issues with pain, fatigue, 
and mobility as the presence of edema can directly contribute to these physical attributes. 
The depressive and anxiety symptoms may reflect the loss of disease control that edema 
represents. The impact of treatment on patient reported outcomes in edematous children 
remains to be explored.
The importance of co-existing conditions in patients with chronic kidney disease may go 
unrecognized in the midst of subspecialty care. Gerson et al demonstrated that children with 
comorbidities had a worse parent-proxy physical, social and emotional scores and children 
self-reported worse social scores [7]. In our study, other health conditions were present in 
nearly 50% of participants. Our data confirm the findings of Gerson et al showing worse 
social-peer interactions. Our study also found worse depression, anxiety, fatigue and 
mobility for patients with increasing number of co-existing conditions in multivariate 
analysis. Taken together these studies emphasize the importance of focusing on the whole 
patient since the pediatric nephrology practice often serves as the medical home for patients 
with chronic kidney disease.
Interestingly, we did not demonstrate a significant difference between individuals with end 
stage kidney disease, pre-end stage kidney disease, and kidney transplant with respect to 
self-reported quality of life. The literature on this topic has shown mixed results when 
comparing patients with renal transplant to children with varying degrees of chronic kidney 
disease and those on dialysis. In studies that have relied on child self-report it is typical not 
to find significant differences in health related quality of life after renal transplant as 
compared to children prior to transplant [4, 27, 29]. One may postulate that the small sample 
size of end stage kidney disease patients in our study may explain the lack of significant 
differences across chronic kidney disease severity. Overall, however, our findings suggest 
that the impact of chronic kidney disease on the health related quality of life in children lies 
with markers of disease activity that directly impact a child including the presence of edema 
and recent hospitalizations.
Limitations of this study should be noted. This study utilized a within-patient comparison 
and did not include healthy controls. This shows the strength of the PROMIS instrument in 
that it is able to detect clinically meaningful differences within disease specific patient 
samples. There are studies currently underway to characterize the PROMIS instrument in 
healthy subjects as well as to characterize minimally important differences that can be used 
to inform analysis of longitudinal within patient comparisons. The PROMIS instrument is 
limited by the age of patients that can provide self-report and was designed for children ages 
8–17 years. At the time of this study only an English version of the Pediatric PROMIS 
instrument was available. Following the launch of this project, PROMIS parent proxy-report 
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items have been developed for age 5 – 17 years. These resources will enrich future research. 
Lastly, this study was cross-sectional and does not document longitudinal changes.
Among the strengths of this study is the inclusion of patients from a wide variety of socio-
economic and clinical backgrounds. This represents one of the broadest patient samplings 
studying patient reported outcomes in children with chronic kidney disease.
Conclusion
This is the first step in the validation process for the pediatric PROMIS instrument in 
chronic kidney disease. Future prospective longitudinal studies, healthy control samples, 
cross-disease and cross-instrument comparisons will be necessary to identify the best use of 
PROMIS in pediatric kidney disease research and patient care environments. This study 
demonstrated that the pediatric PROMIS instrument was sensitive to differences in clinical 
status within a sample of children with chronic kidney disease. The scores were worse with 
clinical indicators of disease activity and with co-existing conditions. Future work will need 
to advance the investigation of the pediatric PROMIS self-report in longitudinal analysis, 
initiate assessment of the parent proxy instrument, and comparison to legacy instruments.
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Comparison of PROMIS scores in children with Chronic Kidney Disease (CKD) to those 
with Nephrotic Syndrome (NS)
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  Male 140 (61.1)
Child’s Age (yrs)
  8–12 80 (34.9)
  13–17 149 (65.1)
Child’s Race
  White 146 (63.8)
  Black or African-American 49 (21.4)
  Asian 8 (3.5)
  Other, Multiple Races 26 (11.4)
Child’s Ethnicity
  Non Hispanic 213 (93.0)
  Hispanic 16 (7.0)
eGFR (n), Mean, (SD)* (n=229), 57 (39)
Disease etiology
  Congenital Urology 114(49.8)
  Glomerular Nephritis, Vasculitis 68 (29.7)
  Other 47 (20.5)
CKD Severity
  Stage I–III 106 (46.2)
  StageIV–V 38 (16.6)
  Renal Transplant 85 (37.1)
Co-Existing conditions (#)
  None 110 (48.0)
  One 69 (30.1)
  ≥ Two 50 (21.8)
Co-Existing conditions:**
  Asthma 34 (14.9)
  ADD/ADHD 29 (12.7)
  Mental Disorders 16 (7.0)
  Overweight 18 (7.9)
  Premature birth 42 (18.3)
  Rheumatic disease 13 (5.7)
Hospitalized in the past 6 months 75 (32.8)
Edema Status
  None 197 (86.0)
  Yes 27 (11.8)
Active edema 28 (12.0)


























Surgery in the past 12 months 77 (33.6)
# of medications per day (n), Mean(SD)) (n=227), 5.1 (3.3)
Steroid Therapy (All)
  None 146 (63.8)
  Alternating day 19 (8.2)
  Daily or more than once/day 59 (25.8)
Parent Report of overweight child 18 (7.9)
Guardian Demographics
Relationship to Child
  Parent 215 (94.0)
  Grandparent 9 (3.9)
  Guardian or Other 5 (2.2)
Education Level
  < High school 17 (7.4)
  High school degree/GED 65 (28.4)
  Some college/technical degree 68 (29.7)
  College degree or more 79 (34.5)
*
eGFR= estimated glomerular filtration rate
**
Parents reported > 1 condition; there were many other conditions in lower frequency (<3%) than listed conditions.
CKD, chronic kidney disease; ADD/ADHD, attention deficit disorder/attention deficit hyperactivity disorder
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